A novel function of API5 (apoptosis inhibitor 5), TLR4-dependent activation of antigen presenting cells

References

• Davis ID, Jefford M, Parente P, Cebon J. Rational approaches to human cancer immunotherapy. J Leukoc Biol. 2003;73:3–29. doi:10.1189/jlb.0502261.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Reviews Immunol. 2005;5:296–306. doi:10.1038/nri1592.
   PubMed Web of Science ®Google Scholar
• Figdor CG, De Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med. 2004;10:475–480. doi:10.1038/nm1039.
   PubMed Web of Science ®Google Scholar
• Morisaki T, Matsumoto K, Onishi H, et al. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives. Hum Cell. 2003;16:175–182. doi:10.1111/j.1749-0774.2003.tb00151.x.
   PubMedGoogle Scholar
• Baek S, Kim YM, Kim SB, Kim CS, Kwon SW, Kim Y, Lee H. Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial. Cell Mol Immunol. 2014.;12:87–95. doi:10.1038/cmi.2014.40
   PubMed Web of Science ®Google Scholar
• Annels NE, Shaw VE, Gabitass RF, Billingham L, Corrie P, Eatock M, Valle J, Smith D, Wadsley J, Cunningham D, et al. The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. Cancer Immunol Immun. 2014;63:175–183. doi:10.1007/s00262-013-1502-y.
   PubMed Web of Science ®Google Scholar
• Urbanski HF, Sorwell KG. Age-related changes in neuroendocrine rhythmic function in the rhesus macaque. Age (Dordr). 2012;34:1111–1121. doi:10.1007/s11357-011-9352-z.
   PubMedGoogle Scholar
• Zhang X, Yu C, Zhao J, Fu L, Yi S, Liu S, Yu T, Chen W. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice. J Gene Med. 2007;9:715–726. doi:10.1002/jgm.1067.
   PubMed Web of Science ®Google Scholar
• Josien R, Li HL, Ingulli E, Sarma S, Wong BR, Vologodskaia M, Steinman RM, Choi Y. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med. 2000;191:495–502. doi:10.1084/jem.191.3.495.
   PubMed Web of Science ®Google Scholar
• Endo H, Saito T, Kenjo A, Hoshino M, Terashima M, Sato T, Anazawa T, Kimura T, Tsuchiya T, Irisawa A, et al. Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients. J Hepatobiliary Pancreat Sci. 2012;19:465–475. doi:10.1007/s00534-011-0457-7.
   PubMed Web of Science ®Google Scholar
• Liu JY, Wu Y, Zhang XS, Yang JL, Li HL, Mao YQ, Wang Y, Cheng X, Li Y-Q, Xia J-C, et al. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immun. 2007;56:1597–1604. doi:10.1007/s00262-007-0305-4.
   PubMed Web of Science ®Google Scholar
• Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I, Pass HI, Gaudino G, Carbone M, Yang H. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 2012;72:3290–3301. doi:10.1158/0008-5472.CAN-11-3481.
   PubMed Web of Science ®Google Scholar
• Krysko O, Love Aaes T, Bachert C, Vandenabeele P, Krysko DV. Many faces of DAMPs in cancer therapy. Cell Death Dis. 2013;4:e631. doi:10.1038/cddis.2013.156.
   PubMed Web of Science ®Google Scholar
• He Y, Zha J, Wang Y, Liu W, Yang X, Yu P. Tissue damage-associated “danger signals” influence T-cell responses that promote the progression of preneoplasia to cancer. Cancer Res. 2013;73:629–639. doi:10.1158/0008-5472.CAN-12-2704.
   PubMed Web of Science ®Google Scholar
• Nace G, Evankovich J, Eid R, Tsung A. Dendritic cells and damage-associated molecular patterns: endogenous danger signals linking innate and adaptive immunity. J Innate Immun. 2012;4:6–15. doi:10.1159/000334245.
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12:860–875. doi:10.1038/nrc3380.
   PubMed Web of Science ®Google Scholar
• Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, Gameiro SR. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer. 2013;133:624–636. doi:10.1002/ijc.28070.
   PubMed Web of Science ®Google Scholar
• Fang H, Ang B, Xu X, Huang X, Wu Y, Sun Y, Wang W, Li N, Cao X, Wan T. TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells. Cell Mol Immunol. 2014;11:150–159. doi:10.1038/cmi.2013.59.
   PubMed Web of Science ®Google Scholar
• Kang TH, Kim YS, Kim S, Yang B, Lee JJ, Lee HJ, Lee J, Jung ID, Han HD, Lee S-H, et al. Pancreatic adenocarcinoma upregulated factor serves as adjuvant by activating dendritic cells through stimulation of TLR4. Oncotarget. 2015;6:27751–27762. doi:10.18632/oncotarget.v6i29.
   PubMedGoogle Scholar
• Tewari M, Yu M, Ross B, Dean C, Giordano A, Rubin R. AAC-11, a novel cDNA that inhibits apoptosis after growth factor withdrawal. Cancer Res. 1997;57:4063–4069.
   PubMed Web of Science ®Google Scholar
• Rigou P, Piddubnyak V, Faye A, Rain JC, Michel L, Calvo F, Poyet J-L. The antiapoptotic protein AAC-11 interacts with and regulates Acinus-mediated DNA fragmentation. EMBO J. 2009;28:1576–1588. doi:10.1038/emboj.2009.106.
   PubMed Web of Science ®Google Scholar
• Morris EJ, Michaud WA, Ji JY, Moon NS, Rocco JW, Dyson NJ. Functional identification of Api5 as a suppressor of E2F-dependent apoptosis in vivo. PLoS Genet. 2006;2:e196. doi:10.1371/journal.pgen.0020196.
   PubMed Web of Science ®Google Scholar
• Basset C, Bonnet-Magnaval F, Navarro MG-J, Touriol C, Courtade M, Prats H, Garmy-Susini B, Lacazette E. Api5 a new cofactor of estrogen receptor alpha involved in breast cancer outcome. Oncotarget. 2017;8. doi:10.18632/oncotarget.v8i32.
   PubMedGoogle Scholar
• Song KH, Cho H, Kim S, Lee HJ, Oh SJ, Woo SR, Hong S-O, Jang HS, Noh KH, Choi CH, et al. API5 confers cancer stem cell-like properties through the FGF2-NANOG axis. Oncogenesis. 2017;6:e285. doi:10.1038/oncsis.2016.87.
   PubMed Web of Science ®Google Scholar
• Cho H, Chung JY, Song KH, Noh KH, Kim BW, Chung EJ, Ylaya K, Kim JH, Kim TW, Hewitt SM, et al. Apoptosis inhibitor-5 overexpression is associated with tumor progression and poor prognosis in patients with cervical cancer. BMC Cancer. 2014;14:545. doi:10.1186/1471-2407-14-545.
   PubMed Web of Science ®Google Scholar
• Noh KH, Kim SH, Kim JH, Song KH, Lee YH, Kang TH, Han HD, Sood AK, Ng J, Kim K, et al. API5 confers tumoral immune escape through FGF2-dependent cell survival pathway. Cancer Res. 2014;74:3556–3566. doi:10.1158/0008-5472.CAN-13-3225.
   PubMed Web of Science ®Google Scholar
• Wang Z, Liu H, Liu B, Ma W, Xue X, Chen J, Zhou Q. Gene.. Gene expression levels of CSNK1A1 and AAC-11, but not NME1, in tumor tissues as prognostic factors in NSCLC patients. Med Sci Monit. 2010;16:CR357–64.
   PubMed Web of Science ®Google Scholar
• Krejci P, Pejchalova K, Rosenbloom BE, Rosenfelt FP, Tran EL, Laurell H, Wilcox WR. The antiapoptotic protein Api5 and its partner, high molecular weight FGF2, are up-regulated in B cell chronic lymphoid leukemia. J Leukoc Biol. 2007;82:1363–1364. doi:10.1189/jlb.0607425.
   PubMed Web of Science ®Google Scholar
• Sasaki H, Moriyama S, Yukiue H, Kobayashi Y, Nakashima Y, Kaji M, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y. Expression of the antiapoptosis gene, AAC-11, as a prognosis marker in non-small cell lung cancer. Lung Cancer. 2001;34:53–57. doi:10.1016/S0169-5002(01)00213-6.
   PubMed Web of Science ®Google Scholar
• Kim JW, Cho HS, Kim JH, Hur SY, Kim TE, Lee JM, Kim I-K, Namkoong SE. AAC-11 overexpression induces invasion and protects cervical cancer cells from apoptosis. Lab Invest. 2000;80:587–594. doi:10.1038/labinvest.3780063.
   PubMed Web of Science ®Google Scholar
• Langenkamp A, Messi M, Lanzavecchia A, Sallusto F. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol. 2000;1:311–316. doi:10.1038/79758.
   PubMed Web of Science ®Google Scholar
• Sayers S, Ulysse G, Xiang Z, He Y. Vaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine development. J Biomed Biotechnol. 2012;2012:1–13. doi:10.1155/2012/831486.
   PubMedGoogle Scholar
• Saenz R, Futalan D, Leutenez L, Eekhout F, Fecteau JF, Sundelius S, Sundqvist S, Larsson M, Hayashi T, Minev B, et al. TLR4-dependent activation of dendritic cells by an HMGB1-derived peptide adjuvant. J Transl Med. 2014;12:211. doi:10.1186/1479-5876-12-211.
   PubMed Web of Science ®Google Scholar
• Rubartelli A, Lotze MT. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol. 2007;28:429–436. doi:10.1016/j.it.2007.08.004.
   PubMed Web of Science ®Google Scholar
• Lin KY, Guarnieri FG, Staveley-O’Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996;56:21–26.
   PubMed Web of Science ®Google Scholar